leishmun
industri
version
fmlsaponin
vaccin
shown
develop
protect
vaccin
dog
vaccin
efficaci
field
canin
viscer
leishmaniasi
cvl
brazil
leishmun
proven
safe
toler
transmissionblock
vaccin
render
vaccin
dog
noninfecti
sand
fli
vector
present
investig
healthi
seroneg
dog
endem
epidem
area
brazil
monitor
leishmun
immunogen
trial
anoth
group
untreat
expos
dog
also
studi
parallel
group
seroneg
day
strong
immunogen
induc
leishmun
vaccin
demonstr
fmlseroconvers
increas
absorb
dth
posit
reaction
increas
skin
test
size
diamet
averag
increas
total
lymphocyt
popul
blood
expect
saponincontain
vaccin
sustain
proport
cell
averag
increas
proport
b
lymphocyt
leishmun
induc
protect
cvl
demonstr
result
asymptomat
dog
end
first
year
healthi
survivor
end
second
year
among
vaccin
dog
compar
asymptomat
survivor
dog
p
monitor
untreat
expos
cohort
spite
low
vaccin
coverag
possibl
detect
p
reduct
belo
horizont
p
reduct
atuba
incid
cvl
among
vaccin
dog
compar
global
incid
cvl
town
respect
preliminari
result
support
potenti
use
leishmun
prevent
cvl
epidem
viscer
leishmaniasi
vl
chronic
sever
protozoa
infect
fatal
untreat
begin
symptom
diseas
canid
zoonosi
zvl
caus
leishmania
chagasi
america
leishmania
infantum
mediterranean
basin
middl
east
anthroponosi
caus
leishmania
donovani
africa
india
asia
nowaday
new
human
case
regist
annual
worldwid
drug
resist
toxic
chemotherapi
increas
diseas
incid
immunocompromis
subject
difficulti
epidemiolog
control
base
upon
sacrif
seroposit
dog
emphas
need
safe
pro
achiev
differ
level
protect
data
field
trial
dna
formul
far
avail
despit
recent
intensif
research
canin
vaccin
two
secondgener
vaccin
nativ
antigen
progress
phase
iii
field
trial
fmlsaponin
liesap
vaccin
fml
fucosemannos
ligand
glycoprot
complex
antigen
human
dog
formul
secondgener
vaccin
quillaja
saponaria
saponin
underw
phase
iiii
trial
becom
leishmun
licens
vaccin
brazil
fml
immunogen
immunoprophylact
immunotherapeut
mice
hamster
canin
field
trial
first
phase
iii
dog
assay
death
symptomat
case
among
placebotr
dog
detect
confirm
parasit
analysi
pcr
death
detect
among
vaccin
infect
confirm
oligosymptomat
dog
result
protect
vaccin
efficaci
second
field
assay
infect
pressur
higher
year
vaccin
death
detect
placebotr
vaccin
dog
result
protect
vaccin
efficaci
protect
last
least
year
concomit
reduct
human
incid
diseas
area
fmlvaccin
also
produc
immunotherapeut
effect
administ
l
donovanior
l
chagasiinfect
dog
still
asymptomat
decreas
canin
human
incid
viscer
leishmaniasi
vaccin
area
mainten
normal
proport
lymphocyt
level
blood
vaccin
dog
indic
dog
vaccin
fmlvaccin
reduc
dog
infect
sand
fli
liesap
mdp
vaccin
secondgener
vaccin
nativ
antigen
recent
use
field
assay
natur
expos
dog
south
franc
trial
dog
show
clinic
andor
serolog
evid
infect
confirm
presenc
parasit
bone
marrow
cultur
pcr
analysi
year
incid
infect
vaccin
versu
placebotr
dog
vaccin
efficaci
author
claim
vaccin
efficaci
base
confirm
infect
sensit
method
pcr
cultur
instead
cvl
death
occur
area
lower
incid
fmlvaccin
unlik
liesap
vaccin
reveal
protect
infect
also
sever
diseas
death
due
cvl
reduc
morbid
mortal
much
stronger
criteria
protect
fmlvaccin
licens
brazil
dog
prophylaxi
zvl
brand
leishmun
dog
vaccin
leishmun
fmllicens
vaccin
infecti
sand
fli
indic
complet
absenc
clinic
sign
parasit
skin
lymph
node
blood
pcramplifi
sampl
expos
untreat
control
hand
symptomat
show
parasit
lymph
node
leishmania
dna
detect
pcr
blood
immunohistochem
reaction
skin
leishmun
transmissionblock
vaccin
use
increas
adjuv
concentr
also
effect
immunotherapi
experiment
cvl
recent
describ
safeti
analysi
leishmun
vaccin
perform
cohort
dog
brazilian
endem
epidem
area
canin
human
viscer
leishmaniasi
vaccin
prove
toler
safe
present
investig
report
immunogen
assay
leishmun
monitor
dog
cohort
confirm
immuno
protect
potenti
previous
describ
fmlsaponin
vaccin
disclos
potenti
use
leishmun
vaccin
interrupt
epidem
six
hundr
healthi
dog
canin
viscer
leishmaniasi
endem
town
atuba
andradina
guararap
bauru
paulo
state
belo
horizont
nova
lima
sete
lagoa
mina
gerai
state
brazil
show
previou
neg
result
leishmaniaserolog
immunofluoresc
assay
select
vaccin
three
dose
leishmun
fort
dodg
anim
health
campina
sp
brazil
interv
subcutan
sc
rout
booster
month
day
vaccin
dog
exclud
due
posit
reaction
sensit
fmlelisa
assay
remain
dog
seroneg
fml
antigen
asymptomat
show
good
physic
condit
becam
trial
group
investig
veterinarian
particip
trial
vaccin
dog
three
dose
leishmun
make
total
dose
anim
monitor
antifml
igg
serum
antibodi
titter
fmlelisa
assay
day
month
intraderm
respons
l
donovani
promastigot
lysat
antigen
month
serum
collect
intraderm
test
carri
inject
vaccin
booster
month
also
clinic
evalu
perform
everi
month
period
alopecia
onychogryphosi
cachexia
anorexia
apathi
dissemin
ulcer
skin
lesion
kerat
renal
failur
loss
weight
lymph
node
enlarg
diarrhoea
record
viscer
leishmaniasi
symptom
vaccin
symptomat
anim
leishmania
infect
confirm
either
pcr
analysi
lymph
node
aspir
andor
blood
sampl
direct
microscop
observ
leishmania
amastigot
giemsa
stain
lymph
node
smear
leishmun
vaccin
dog
cohort
includ
anim
differ
breed
mongrel
dog
anim
previous
vaccin
distemp
parvovirosi
parainfluenza
viru
leptospirosi
coronavirus
type
adenovirus
rabi
ethic
reason
veterinarian
abl
keep
untreat
expos
control
dog
popul
purpos
comparison
asymptomat
fmlseroneg
dog
anoth
endem
area
jardim
progresso
natal
rn
brazil
similar
canin
incid
includ
studi
expos
untreat
group
investig
manipul
perform
anim
conduct
ensur
minim
anim
suffer
recommend
nih
regul
leishmun
prophylact
vaccin
dose
compos
lyophil
fml
antigen
adjuv
saponin
reconstitut
ml
nacl
steril
salin
solut
moment
vaccin
administ
subcutan
fmlvaccin
leishmun
patent
inpi
number
march
assign
universidad
feder
rio
de
janeiro
brazil
first
secondgener
vaccin
licens
leishmaniasi
sinc
june
determin
inject
dog
intraderm
inner
aspect
right
hind
leg
ml
l
donovani
freezethaw
antigen
contain
g
protein
nacl
steril
salin
solut
stationari
phase
promastigotesml
left
hind
leg
receiv
ml
salin
measur
increas
intraderm
reaction
perform
h
antigen
inject
indur
area
mark
time
valu
salin
control
subtract
reaction
due
leishmania
antigen
reaction
show
diamet
mm
consid
posit
month
vaccin
pbmc
randomli
chosen
leishmun
vaccin
dog
atuba
andradina
analys
flow
cytometri
three
millilit
blood
cephal
vein
collect
dog
heparintub
transport
room
temperatur
process
h
collect
ex
vivo
analysi
l
blood
incub
min
room
temperatur
l
one
follow
monoclon
antibodi
dilut
fac
dil
solut
fcssupplement
pb
buffer
fac
dil
solut
use
neg
control
period
ml
pbsw
pb
buffer
bovin
serum
albumin
sodium
azid
ad
tube
mixtur
homogenis
centrifug
rpm
room
temperatur
min
supernat
aspir
pellet
homogenis
ad
l
antirat
fitc
conjug
serotec
uk
except
fac
dil
cell
control
time
l
fitclabel
mous
monoclon
antibodi
immunotech
co
marseil
franc
use
direct
immunofluoresc
procedur
suspens
homogenis
incub
min
room
temperatur
dark
treat
ml
dilut
lysi
solut
vortex
homogenis
becton
dickinson
usa
mixtur
incub
min
room
temperatur
dark
centrifug
rpm
min
supernat
discard
pelletcontain
tube
invert
absorb
paper
procedur
repeat
twice
addit
ml
pb
pellet
homogenis
care
final
fix
l
formaldehydepb
rel
immunofluoresc
cell
count
total
event
measur
becton
dickinson
facscalibur
apparatu
analys
use
window
multipl
document
interfac
flow
cytometri
applic
winmdi
version
softwar
control
fac
analysi
pbmc
nine
normal
healthi
untreat
dog
also
perform
comparison
proport
carri
use
test
test
signific
differ
group
use
confid
interv
averag
five
hundr
fifti
dog
previous
assay
leishmun
safeti
analysi
also
monitor
vaccineinduc
immunogen
trial
anoth
group
untreat
expos
dog
also
studi
differ
two
group
vaccin
highli
signific
variabl
p
tabl
vaccin
untreat
group
seroneg
day
strong
fmlseroconvers
detect
complet
vaccin
day
time
untreat
control
develop
antifml
antibodi
due
exposur
natur
infect
vaccin
increas
number
dog
posit
tabl
twoyear
evolut
immunogen
incid
zvl
cohort
leishmun
delay
type
hypersensit
respons
dth
leishmani
lysat
posit
vaccin
dog
month
increas
along
time
tabl
disclos
desir
protect
vaccin
cvl
leishmun
prophylact
vaccin
enhanc
humor
respons
also
trigger
cellular
immun
respons
parasit
well
size
skin
test
reaction
use
measur
potenc
vaccin
mean
sd
diamet
skin
test
month
mm
n
skin
test
diamet
significantli
increas
month
n
p
dth
reaction
posit
vaccin
result
confirm
natur
booster
endem
area
sustain
humor
respons
leishmun
vaccin
contribut
enhanc
specif
antil
chagasi
cellular
immun
respons
known
respons
protect
cvl
vaccin
untreat
dog
healthi
begin
studi
untreat
dog
group
develop
greater
number
zvl
symptom
along
time
reach
cohort
end
first
year
meanwhil
clinic
sign
detect
vaccin
period
tabl
accordingli
cumul
proport
death
due
confirm
zvl
untreat
dog
reach
cohort
vaccin
dog
die
zvl
trial
result
indic
strong
protect
prophylact
effect
leishmun
seroneg
dog
endem
area
tabl
summar
result
immunophenotyp
analysi
pbmc
randomli
select
sampl
dog
collect
great
differ
incid
zvl
disclos
vaccin
control
tabl
could
partial
due
differ
infect
pressur
town
leishmun
vaccin
dog
untreat
control
locat
howev
compar
incid
zvl
leishmun
vaccin
dog
incid
total
dog
popul
town
vaccineinduc
protect
also
evid
tabl
show
offici
data
mean
valu
canin
incid
zvl
period
show
zvl
incid
belo
horizont
decreas
total
popul
p
leishmun
vaccin
dog
first
year
vaccin
use
strike
effect
prophylact
vaccin
seen
atuba
incid
zvl
decreas
total
popul
vaccin
p
lead
reduct
zvl
incid
thu
confirm
strong
protect
effect
leishmun
cohort
vaccin
dog
analys
investig
previous
use
safeti
analysi
leishmun
vaccin
confirm
formul
toler
safe
investig
confirm
strong
immunogen
leishmun
vaccin
previous
shown
fmlsaponin
vaccin
field
indic
commerci
formul
maintain
characterist
laboratoryprepar
vaccin
soon
complet
vaccin
percent
seroposit
fml
dog
treat
fmlsaponin
vaccin
reach
leishmun
vaccin
indic
earlier
achiev
humor
respons
induc
commerci
formul
import
indic
vaccin
potenc
humor
respons
also
sustain
high
level
month
vaccin
probabl
due
natur
booster
effect
l
chagasiinfect
sand
fli
endem
area
convers
previou
kennel
experi
nonendem
area
show
leishmun
unexpos
dog
decreas
absorb
day
month
vaccin
unpublish
result
twelv
month
vaccin
posit
dth
respons
leishmani
antigen
present
fmlsaponinvaccin
dog
mm
averag
skin
test
diamet
leishmun
vaccin
dog
show
slightli
larger
diamet
skin
test
mm
indic
besid
antibodi
respons
induct
cellular
immun
respons
leishmania
lysat
also
preserv
commerci
formul
leishmun
vaccin
induc
increas
total
lymphocyt
popul
blood
also
observ
dog
immunotherapi
fmlsaponin
vaccin
expect
vaccin
contain
saponin
adjuv
q
saponaria
molina
relat
hydrophob
normonoterpen
moieti
also
present
deacyl
saponin
q
saponaria
molina
deacyl
saponin
calliandra
pulcherrima
lack
hydrophob
moieti
evid
involv
lymphocyt
protect
intracellular
parasit
infect
increas
recent
mice
fail
control
leishmania
parasit
growth
also
specif
cell
prime
natur
infect
human
vaccin
secret
restimul
vitro
leishmania
antigen
natur
infect
asymptomat
dog
increas
level
lymphocyt
appear
major
phenotyp
featur
well
dog
bear
lower
parasit
load
indic
correl
natur
protect
effect
observ
l
infantum
lysat
vaccin
increas
cell
observ
vaccin
q
saponaria
saponincontain
vaccin
fmlquila
fmlsaponin
r
leishmun
l
brasilensi
lysatesaponin
vaccin
intens
cell
prolifer
increas
nitric
oxid
product
vitro
stimul
l
chagasi
solubl
antigen
suggest
induct
potenti
resist
profil
total
level
lymphocyt
expect
decreas
advanc
canin
viscer
leishmaniasi
specif
decreas
cell
correl
dog
infect
sand
fli
inde
averag
percent
valu
lymphocyt
natur
infect
dog
viscer
leishmaniasi
hand
vaccin
zvl
expect
expand
sustain
cell
level
expans
sustent
cell
level
dog
treat
l
infantum
vaccin
immunochemotherapi
fmlquila
vaccin
fmlsaponin
r
leishmun
vaccin
sustain
cell
found
also
investig
dog
vaccin
leishmun
sustain
l
chagasispecif
cell
proport
found
dog
treat
leishmun
infect
indic
commerci
formul
maintain
immunogen
potenc
demonstr
fmlsaponin
vaccin
prophylaxi
immunotherapi
zvl
leishmun
prophylact
vaccin
contain
mg
leishmun
immunotherapeut
l
brasiliensi
vaccin
contain
riedel
de
haen
saponin
maintain
normal
level
lymphocyt
vaccin
unexpos
expos
challeng
dog
higher
proport
cell
detect
investig
leishmun
vaccin
dog
level
cell
higher
vaccine
mean
averag
fell
outsid
interv
normal
dog
increas
b
cell
level
also
found
dog
vaccin
l
brasiliensissaponin
vaccin
use
adjuv
includ
leishmun
unexpos
dog
vaccin
leishmun
increas
total
leishmaniaspecif
b
circul
lymphocyt
synchron
induct
intens
humor
respons
also
posit
correl
found
pbmc
prolifer
respons
l
chagasi
antigen
b
cell
consid
indic
major
apc
function
cell
hand
decreas
b
cell
proport
expect
occur
untreat
infect
dog
advanc
zvl
also
exhibit
hypergammaglobulinemia
hallmark
human
canin
viscer
leishmaniasi
fact
suggest
b
lymphocyt
popul
increas
vaccin
leishmun
involv
mere
expans
total
humor
respons
increas
specif
synthesi
antifml
antibodi
relat
protect
blockag
transmiss
vl
field
investig
demonstr
strong
immunogen
leishmun
healthi
expos
dog
epidem
area
consequ
exhibit
strong
sustain
humor
cellular
immun
respons
parasit
classic
phase
iii
trial
random
doubleblind
select
control
could
perform
ethic
restrict
veterinarian
epidem
area
refus
includ
untreat
healthi
dog
expos
control
leishmun
induc
protect
zvl
howev
suggest
result
asymptomat
dog
end
first
year
healthi
survivor
end
second
year
among
vaccin
dog
compar
asymptomat
survivor
dog
monitor
untreat
expos
cohort
anoth
endem
area
although
vaccin
zvl
consid
effici
tool
erad
human
canin
viscer
leishmaniasi
leishmun
first
vaccin
world
licens
zvl
vaccin
coverag
brazil
still
low
spite
incid
zvl
among
vaccin
dog
belo
horizont
suffer
signific
reduct
p
p
signific
declin
atuba
compar
global
incid
zvl
town
respect
thu
preliminari
result
support
potenti
use
leishmun
prevent
zvl
epidem
